Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Clarity Pharmaceuticals Ltd

CU6.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Small Cap Analyst: BUY

Last Close

$1.64

▲ +0.44%

Market Cap $612.37M · Vol 1.45M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$612.37M

Small Cap

Div Yield

N/A

EPS Growth

-7.81%

YoY

RSI (14)

37.60

Momentum

Beta

1.84

vs Market

52W High

$4.23

56.86% below

52W Low

$1.30

32.27% above

Volume

1.45M

Avg 2.16M

P/B

4.29

Price-to-book

ROE

-77.62%

Return on equity

Free Float

78.85%

Public shares

Shariah Compliance8 STANDARDS

✗ Clarity Pharmaceuticals Ltd (CU6.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CU6.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-9.16%

-9.52%

-1.30%

-26.69%

YTD

-32.54%

-27.16%

+157.01%

+61.06%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-74,132,222.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-77.62%
ROA · ROIC	-70.80% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	4.29
P/FCF	N/A
EPS Growth	-7.81%
Outstanding Shares	373.08M

Technical Indicators

50-Day SMA	$1.74
200-Day SMA	$2.11
RSI (14)	37.60
Beta	1.84
52-Week High	$4.23
52-Week Low	$1.30

Volume Today	1.45M
Avg Daily Volume (30D)	2.16M
Relative Volume	0.67x
Volatility (10D)	73.81
Volatility (30D)	74.12
Free Float	78.85%

Analyst Consensus

BUY

Current Price $1.64

Mean Target $5.08

52W Low$1.30 52W High$4.23

Current

Target

$1.30 $4.23

Current Analyst target

+209.32% upside potential · 4 analysts

Identifiers

ExchangeASX

FIGIBBG011WVJ0S1

ISINAU0000165375

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 26, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.57% ARGX.BR argenx SE -2.06% ARGX argenx SE -1.93% INSM Insmed Inc -0.31% 2269.HK WuXi Biologics (Cayman) Inc -3.00%

Company Profile

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.